001     120520
005     20240228145450.0
024 7 _ |a 10.1084/jem.20160311
|2 doi
024 7 _ |a pmid:28289053
|2 pmid
024 7 _ |a pmc:PMC5379968
|2 pmc
024 7 _ |a 0022-1007
|2 ISSN
024 7 _ |a 1540-9538
|2 ISSN
024 7 _ |a altmetric:17408992
|2 altmetric
037 _ _ |a DKFZ-2017-00949
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Fantin, Alessandro
|b 0
245 _ _ |a VEGF165-induced vascular permeability requires NRP1 for ABL-mediated SRC family kinase activation.
260 _ _ |a New York, NY
|c 2017
|b Rockefeller Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1524654446_18387
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The vascular endothelial growth factor (VEGF) isoform VEGF165 stimulates vascular growth and hyperpermeability. Whereas blood vessel growth is essential to sustain organ health, chronic hyperpermeability causes damaging tissue edema. By combining in vivo and tissue culture models, we show here that VEGF165-induced vascular leakage requires both VEGFR2 and NRP1, including the VEGF164-binding site of NRP1 and the NRP1 cytoplasmic domain (NCD), but not the known NCD interactor GIPC1. In the VEGF165-bound receptor complex, the NCD promotes ABL kinase activation, which in turn is required to activate VEGFR2-recruited SRC family kinases (SFKs). These results elucidate the receptor complex and signaling hierarchy of downstream kinases that transduce the permeability response to VEGF165. In a mouse model with choroidal neovascularisation akin to age-related macular degeneration, NCD loss attenuated vessel leakage without affecting neovascularisation. These findings raise the possibility that targeting NRP1 or its NCD interactors may be a useful therapeutic strategy in neovascular disease to reduce VEGF165-induced edema without compromising vessel growth.
536 _ _ |a 321 - Basic Concepts (POF3-321)
|0 G:(DE-HGF)POF3-321
|c POF3-321
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Lampropoulou, Anastasia
|b 1
700 1 _ |a Senatore, Valentina
|b 2
700 1 _ |a Brash, James T
|b 3
700 1 _ |a Prahst, Claudia
|0 0000-0002-6412-1907
|b 4
700 1 _ |a Lange, Clemens A
|0 0000-0002-2580-6823
|b 5
700 1 _ |a Liyanage, Sidath E
|b 6
700 1 _ |a Raimondi, Claudio
|b 7
700 1 _ |a Bainbridge, James W
|b 8
700 1 _ |a Augustin, Hellmut G
|0 0000-0002-7173-4242
|b 9
700 1 _ |a Ruhrberg, Christiana
|0 0000-0002-3212-9381
|b 10
773 _ _ |a 10.1084/jem.20160311
|g Vol. 214, no. 4, p. 1049 - 1064
|0 PERI:(DE-600)1477240-1
|n 4
|p 1049 - 1064
|t Journal of experimental medicine
|v 214
|y 2017
|x 1540-9538
909 C O |p VDB
|o oai:inrepo02.dkfz.de:120520
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 0000-0002-7173-4242
913 1 _ |a DE-HGF
|l Herz-Kreislauf-Stoffwechselerkrankungen
|1 G:(DE-HGF)POF3-320
|0 G:(DE-HGF)POF3-321
|2 G:(DE-HGF)POF3-300
|v Basic Concepts
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J EXP MED : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b J EXP MED : 2015
920 1 _ |0 I:(DE-He78)A190-20160331
|k A190
|l Vaskuläre Onkologie und Metastasierung
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A190-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21